Enhancement of graft survival and sensorimotor behavioral recovery in rats undergoing transplantation with dopaminergic cells exposed to glial cell line-derived neurotrophic factor

Journal of Neurosurgery

Volumn 88, Issue 6, 1998, Pages 1088-1095

  Mehta, Vivek ^a   Hong, Murray ^a   Spears, Julian ^a   Mendez, Ivar ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Glial cell line derived neurotrophic factor; Graft survival; Neural transplantation; Parkinson's disease; Rat

Indexed keywords

NEUROTROPHIC FACTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; GENETIC ENGINEERING AND GENE TECHNOLOGY; GRAFT SURVIVAL; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION;

EID: 0031812748     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1998.88.6.1088     Document Type: Article

References (37)

1. Abercrombie M: Estimation of nuclear population from microtome sections. Anat Rec 94:239-247, 1946
2. Apostolides C, Sanford E, Hong M, et al: Glial cell line-derived neurotrophic factor improves intrastriatal graft survival of stored dopaminergic cells. Neuroscience 83:363-372, 1998
3. Braughler JM, Hall ED, Jacobsen EJ, et al: The 21-aminosteroids: potent inhibitors of lipid peroxidation for the treatment of central nervous system trauma and ischemia. Drug Future 14:143-152, 1989
4. Dunnett SB, Whishaw IQ, Rogers DC, et al: Dopamine-rich grafts ameliorate whole body motor asymmetry and sensory neglect but not independent limb use in rats with 6-hydroxydopamine lesions. Brain Res 415:63-78, 1987
5. Freed CR, Breeze RE, Rosenberg NL, et al: Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med 327:1549-1555, 1992
6. Freed WJ, Perlow MJ, Karoum F, et al: Restoration of dopaminergic function by grafting of fetal rat substantia nigra to the caudate nucleus: long-term behavioral, biochemical, and histochemical studies. Ann Neurol 8:510-519, 1980
7. Freeman TB, Olanow CW, Hauser RA, et al: Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Ann Neurol 38:379-388, 1995
8. Gash DM, Zhang Z, Ovadia A, et al: Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380: 252-255, 1996
9. Hoffer BJ, Hoffman A, Bowenkamp K, et al: Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 182:107-111, 1994
10. Hou JGG, Lin LFH, Mytilineou C: Glial cell line-derived neurotrophic factor exerts neurotrophic effects on dopaminergic neurons in vitro and promotes their survival and regrowth after damage by 1-methyl-4-phenylpyridinium. J Neurochem 66: 74-82, 1996
11. Hudson J, Granholm AC, Gerhardt GA, et al: Glial cell line-derived neurotrophic factor augments midbrain dopaminergic circuits in vivo. Brain Res Bull 36:425-432, 1995
12. Johansson M, Friedemann M, Hoffer B, et al: Effects of glial cell line-derived neurotrophic factor on developing and mature ventral mesencephalic grafts in oculo. Exp Neurol 134:25-34, 1995
13. Kassell NF, Haley EC Jr, Apperson-Hansen C, et al: Randomized, double-blind vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. J Neurosurg 84:221-228, 1996
14. Kearns CM, Gash DM: GDNF protects nigral dopamine neurons against 6-hydroxydopamine in vivo. Brain Res 672: 104-111, 1995
15. Lin LF, Doherty DH, Lile JD, et al: GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132, 1993
16. Mayer E, Dunnett SB, Pellitteri R, et al: Basic fibroblast growth factor promotes the survival of embryonic ventral mesencephalic dopaminergic neurons - I. Effects in vitro. Neuroscience 56:379-388, 1993
17. Mendez I, Sadi D, Hong M: Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants. J Neurosci 16:7216-7227, 1996
18. Montoya CP, Astell S, Dunnett SB: Effects of nigral and striatal grafts on skilled forelimb use in the rat. Progr Brain Res 82:459-466, 1990
19. Nakao N, Frodl EM, Duan WM, et al: Lazaroids improve the survival of grafted rat embryonic dopamine neurons Proc Natl Acad Sci USA 91:12408-12412, 1994
20. Nikkhah G, Bentlage C, Cunningham MG, et al: Intranigral fetal dopamine grafts induce behavioural compensation in the rat Parkinson model. J Neurosci 14:3449-3461, 1994
21. Nikkhah G, Cunningham MG, Jödicke A, et al: Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model. Brain Res 633:133-143, 1994
22. Nikkhah G, Duan WM, Knappe U, et al: Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model. Neuroscience 56:33-43, 1993
23. Nikkhah G, Olsson M, Eberhard J, et al: A microtransplantation approach for cell suspension grafting in the rat Parkinson model: a detailed account of the methodology. Neuroscience 63:57-72, 1994
24. Olsson M, Nikkhah G, Bentlage C, et al: Forelimb akinesia in the rat parkinsonian model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15:3863-3875, 1995
25. Opacka-Juffry J, Ashworth S, Hume SP, et al: GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET. Neuroreport 7:348-352, 1995
26. Perlow MJ, Freed WJ, Hoffer BJ, et al: Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science 204:643-647, 1979
27. Redmond DE, Sladek JR Jr, Roth RH, et al: Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine Lancet 1:1125-1127, 1986
28. Rioux L, Gaudin DP, Bui LK, et al: Correlation of functional recovery after a 6-hydroxydopamine lesion with survival of grafted fetal neurons and release of dopamine in the striatum of the rat. Neuroscience 40:123-131, 1991
29. Rosenblad C, Martinez-Serrano A, Björklund A: Glial cell line-derived neurotrophic factor increases survival, growth and function of intrastriatal fetal nigral dopaminergic grafts. Neuroscience 75:979-985, 1966
30. Sinclair SR, Svendsen CN, Torres EM, et al: GDNF enhances dopaminergic cell survival and fibre outgrowth in embryonic nigral grafts. Neuroreport 7:2547-2552, 1996
31. Spencer DD, Robbins RJ, Naftolin F, et al: Unilateral transplantation of human fetal mesencephalic tissue into the caudate nucleus of patients with Parkinson's disease. N Engl J Med 327:1541-1548, 1992
32. Strömberg I, Björklund L, Johansson M, et al: Glial cell line-derived neurotrophic factor is expressed in the developing but not adult striatum and stimulates developing dopamine neurons in vivo. Exp Neurol 124:401-412, 1993
33. Takayama H, Ray J, Raymon HK, et al: Basic fibroblast growth factor increases dopaminergic graft survival and function in a rat model of Parkinson's disease. Nat Med 1:53-58, 1995
34. Tomac A, Lindqvist E, Lin LFH, et al: Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339, 1995
35. Tomac A, Widenfalk J, Lin LF, et al: Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci USA 92:8274-8278, 1995
36. Winkler C, Sauer H, Lee CS, et al: Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergi neurons in a rat model of Parkinson's disease. J Neurosci 16: 7206-7215, 1996
37. Yurek DM, Lu W, Hipkens S, et al: BDNF enhances the functional reinnervation of the striatum by grafted fetal dopamine neurons. Exp Neurol 137:105-118, 1996